Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exicure, Inc.
  6. Summary
    XCUR   US30205M1018

EXICURE, INC.

(XCUR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/20/2022 01/21/2022 01/24/2022 01/25/2022 01/26/2022 Date
0.1645(c) 0.1579(c) 0.1573(c) 0.1629(c) 0.1648(c) Last
9 003 006 3 475 186 6 004 064 21 254 720 70 295 105 Volume
-0.96% -4.01% -0.38% +3.56% +1.17% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 0,90 M - -
Net income 2021 -56,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,23x
Yield 2021 -
Sales 2022 10,1 M - -
Net income 2022 -71,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,38x
Yield 2022 -
Capitalization 17,9 M 17,9 M -
Capi. / Sales 2021 19,9x
Capi. / Sales 2022 1,77x
Nbr of Employees 77
Free-Float -
More Financials
Company
Exicure, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its spherical nucleic acid (SNA) technology. The Company is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNA-based therapeutic candidate, for the intrathecal treatment of friedreichÔÇÖs ataxia (FA).... 
More about the company
Ratings of Exicure, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about EXICURE, INC.
01/26Thinking about buying stock in Exicure, Vaccinex, BioNano Genomics, Mind Medicine, or M..
PR
01/26Top Premarket Gainers
MT
01/18EXICURE, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibi..
AQ
01/18Exicure, Inc. Appoints Elias D. Papadimas as Corporate Secretary
CI
01/18Exicure, Inc. Promotes Elias D. Papadimas to Chief Financial Officer
CI
01/17SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exicu..
PR
01/06SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims
PR
01/05EXICURE, INC. : Termination of a Material Definitive Agreement, Results of Operations and ..
AQ
2021SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exicu..
PR
2021XCUR SHAREHOLDER ALERT : Robbins LLP Reminds Investors of Class Action Against Exicure, In..
BU
2021EXICURE : STRICTLY CONFIDENTIAL - Form 8-K
PU
2021EXICURE, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Fina..
AQ
2021XCUR SHAREHOLDERS : Robbins LLP Informs Investors of Class Action Against Exicure, Inc. (X..
BU
2021Exicure Launches Common Stock, Warrant Offering
MT
2021Exicure, Inc. Announces $11.5 Million Registered Direct Offering Priced At-The-Market U..
BU
More news
News in other languages on EXICURE, INC.
01/18Exicure, Inc. nomme Elias D. Papadimas au poste de secrétaire général.
2021Exicure propose une offre d'actions ordinaires et de bons de souscription.
2021Earnings Flash (XCUR) EXICURE affiche un revenu de 79 000 $ au deuxième trimestre
2021Exicure collabore avec Ipsen pour développer des traitements potentiels pour les troubl..
2021Les valeurs à suivre aujourd'hui à Paris Lundi 2 août 2021
More news
Analyst Recommendations on EXICURE, INC.
More recommendations
Chart EXICURE, INC.
Duration : Period :
Exicure, Inc. Technical Analysis Chart | XCUR | US30205M1018 | MarketScreener
Technical analysis trends EXICURE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 0,16 $
Average target price 3,20 $
Spread / Average Target 1 842%
EPS Revisions
Managers and Directors
Brian C. Bock President, Chief Executive Officer & Director
Elias D. Papadimas Chief Financial Officer & Secretary
Timothy P. Walbert Chairman
David A. Giljohann Chief Technology Officer
Matthias G. Schroff Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
EXICURE, INC.-18.46%18
GILEAD SCIENCES, INC.-7.26%84 470
REGENERON PHARMACEUTICALS-4.16%63 282
VERTEX PHARMACEUTICALS3.18%57 608
WUXI APPTEC CO., LTD.-12.11%47 873
BIONTECH SE-37.66%38 812